Hua Medicine Successfully Completes Initial Public Offering and Listing on the Hong Kong Stock Exchange
Hong Kong, September 14, 2018
Hua Medicine, a China-based drug development company with a focus on developing a global first-in-class oral drug for the treatment of Type 2 diabetes, successfully completed its initial public offering, or IPO, and listing on the Hong Kong Stock Exchange.
The IPO priced at HK$8.28 per share, with a total offering size of 104,756,000 shares, before over-allotments, raising approximately HK$867 million with a market capitalization of approximately HK$8,710 million immediately after the IPO.
The Global Sponsors for the IPO were Goldman Sachs (Asia) L.L.C. and CLSA Capital Markets Limited, the Joint Bookrunners were Goldman Sachs (Asia) L.L.C., CLSA Limited and UBS AG Hong Kong Branch and the Joint Lead Managers were Goldman Sachs (Asia) L.L.C, CLSA Limited, UBS AG Hong Kong Branch and Guotai Junan Securities (Hong Kong) Limited.Back to News